FDMT
What one share of 4D Molecular Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients.
4D Molecular Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.42 |
|---|---|
| Profit | −$2.77 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | −$2.41 |
| Cash and investments | $7.80 |
| Debt | $0.35 |
| Book value | $7.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$9.59 | $0.62 | −$7.76 | — | −$14.09 |
| 2020 | — | −$8.82 | $0.16 | −$8.07 | — | — |
| 2021 | — | −$2.57 | $0.33 | −$2.82 | — | $9.90 |
| 2022 | — | −$3.32 | $0.36 | −$3.04 | — | $7.09 |
| 2023 | — | −$2.58 | $0.07 | −$2.01 | — | $7.15 |
| 2024 | — | −$2.98 | $0.07 | −$2.57 | — | $11.15 |
| 2025 | $1.47 | −$2.42 | $0.01 | −$1.89 | — | $8.78 |